Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas

Journal of Pathology

Volumn 224, Issue 3, 2011, Pages 328-333

  Wiegand, Kimberly C ^a,b   Lee, Anna F ^b,c   Al Agha, Osama M ^c,d   Chow, Christine ^d   Kalloger, Steve E ^b   Scott, David W ^a   Steidl, Christian ^a   Wiseman, Sam M ^b,e   Gascoyne, Randy D ^a   Gilks, Blake ^b,c,d   Huntsman, David G ^a,b,d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d Genetic Pathology Evaluation Centre   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

Author keywords

ARID1A; BAF250a; chromatin remodelling; endometrial cancer; SWI SNF

Indexed keywords

PROTEIN BAF 250 A; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG;

ARID 1 A GENE; ARTICLE; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER GRADING; CHROMATIN; COLON CARCINOMA; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM SARCOMA; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; GENE LOSS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG CARCINOMA; MANTLE CELL LYMPHOMA; MOUTH CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECTUM CARCINOMA; STOMACH CARCINOMA; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958238185     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2911     Document Type: Article

References (10)

1. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
2. Jones S, Wang TL, Shih I, et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
3. Huang J, Zhao YL, Li Y, et al., Genomic and functional evidence for an ARID1A tumour suppressor role. Genes Chromosomes Cancer 2007; 46: 745-750. (Pubitemid 46912345)
4. Maeda D, Mao T-L, Fukayama M, et al., Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11: 5120-5128.
5. Alkushi A, Clarke BA, Akbari M, et al., Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007; 20: 1156-1165. (Pubitemid 47609063)
6. Sif S, Saurin AJ, Imbalzano AN, et al., Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes. Genes Dev 2001; 15: 603-618. (Pubitemid 32205148)
7. Wang W, Xue Y, Zhou S, et al., Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev 1996; 10: 2117-2130. (Pubitemid 26303868)
8. Reisman D, Glaros S, Thompson EA,. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
9. Gao X, Tate P, Hu P, et al., ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci USA 2008; 105: 6656-6661. (Pubitemid 351754562)
10. Clarke BA, Gilks CB,. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 2010; 63: 410-415.